CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease

被引:48
作者
Thompson, JF
Durham, LK
Lira, ME
Shear, C
Milos, PM
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
[2] Pfizer Global Res & Dev, New London, CT 06320 USA
关键词
polymorphisms; cardiovascular disease; cholesteryl ester transfer protein;
D O I
10.1016/j.atherosclerosis.2005.01.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To better understand the role of cholesteryl ester transfer protein (CETP) in cardiovascular disease, nine polymorphisms spanning the gene from the upstream promoter region to beyond the 3'UTR were genotyped in 2553 individuals from multiple ethnic groups and with different cardiovascular disease profiles. The frequency of four of these SNPs varied by 40-300% between Caucasians and African Americans. SNPs in each ethnic group fell into two haploblocks with significant linkage disequilibrium within each block. SNPs in the 5' haploblock were significantly associated with HDL cholesterol while SNPs in the 3' haploblock were, at best, only weakly associated with HDL-C. One SNP in the 3' haploblock (rs 1800774 in intron 12) was highly associated with history of myocardial infarction even though it was not associated with HDL-C. This association was driven by the effect in Caucasian women where 11.9% of the women with no history of MI are homozygous for the less common allele while 23.7% of those with a history of MI share this genotype. In addition, this SNP was highly associated with BMI among Caucasians (p < 0.0001). The association of HDL-C with CETP genotype was found to be independent of smoking or alcohol consumption. These results replicate some earlier findings and also help to explain some of the apparent contradictions in the literature surrounding the role of CETP in modulating HDL-C and cardiovascular disease. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 37 条
[11]   Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency -: Veterans Affairs HDL Cholesterol Intervention Trial [J].
Brousseau, ME ;
O'Connor, JJ ;
Ordovas, JM ;
Collins, D ;
Otvos, JD ;
Massov, T ;
McNamara, JR ;
Rubins, HB ;
Robins, SJ ;
Schaefer, EJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1148-1154
[12]   The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease [J].
Carlquist, JF ;
Muhlestein, JB ;
Horne, BD ;
Hart, NI ;
Bair, TL ;
Molhuizen, HOF ;
Anderson, JL .
AMERICAN HEART JOURNAL, 2003, 146 (06) :1007-1014
[13]  
Chen XN, 1999, GENOME RES, V9, P492
[14]   Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J].
Clark, RW ;
Sutfin, TA ;
Ruggeri, RB ;
Willauer, AT ;
Sugarman, ED ;
Magnus-Aryitey, G ;
Cosgrove, PG ;
Sand, TM ;
Wester, RT ;
Williams, JA ;
Perlman, ME ;
Bamberger, MJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :490-497
[15]   Functional analysis of the polypyrimidine tract in pre-mRNA splicing [J].
Coolidge, CJ ;
Seely, RJ ;
Patton, JG .
NUCLEIC ACIDS RESEARCH, 1997, 25 (04) :888-895
[16]  
Corbex M, 2000, GENET EPIDEMIOL, V19, P64, DOI 10.1002/1098-2272(200007)19:1<64::AID-GEPI5>3.0.CO
[17]  
2-E
[18]   New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels - Role of Sp1/Sp3 in transcriptional regulation [J].
Dachet, C ;
Poirier, O ;
Cambien, F ;
Chapman, J ;
Rouis, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :507-515
[19]   The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: No interaction with the response to pravastatin therapy and no effects on cardiovascular outcome - A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy [J].
de Grooth, GJ ;
Zerba, KE ;
Huang, SP ;
Tsuchihashi, Z ;
Kirchgessner, T ;
Belder, R ;
Vishnupad, P ;
Hu, BH ;
Klerkx, AHEM ;
Zwinderman, AH ;
Jukema, JW ;
Sacks, FM ;
Kastelein, JJP ;
Kuivenhoven, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) :854-857
[20]   The -629C &gt; A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men [J].
Eiriksdottir, G ;
Bolla, MK ;
Thorsson, B ;
Sigurdsson, G ;
Humphries, SE ;
Gudnason, V .
ATHEROSCLEROSIS, 2001, 159 (01) :187-192